{"id":1159,"date":"2021-10-26T12:00:44","date_gmt":"2021-10-26T12:00:44","guid":{"rendered":""},"modified":"2021-12-07T15:57:22","modified_gmt":"2021-12-07T15:57:22","slug":"page-1431","status":"publish","type":"post","link":"https:\/\/copolad.fiiapp.quentalstaging.com\/es\/page-1431\/","title":{"rendered":"Medical use of cannabis and cannabinoids: questions and answers for policymaking"},"content":{"rendered":"<div id=\"articleHeader\"><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen-Sans, Ubuntu, Cantarell, 'Helvetica Neue', sans-serif;\">EMCDDA<\/strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen-Sans, Ubuntu, Cantarell, 'Helvetica Neue', sans-serif;\">. European Monitoring Centre for Drugs and Drug Addiction<\/span><\/div>\n<section>\n<div>\n<p>What is the evidence base for the medical use of cannabis and cannabinoids? What is the difference between cannabis preparations and medicinal products and why is this important? How is this issue regulated in the EU? These and other questions are explored in this report which responds to growing interest in this topic as more European countries develop policies and practice in this area.<\/p>\n<\/div>\n<div>\n<div>\n<div>\n<div>\n<div>\n<p>La Comisi\u00f3n Europea est\u00e1 preparando una tercera fase de este programa, por lo que COPOLAD volver\u00e1 a principios de 2021.<\/p>\n<p><a title=\"Acceder en ingl\u00e9s\" href=\"https:\/\/copolad.eu\/wp-content\/uploads\/attachments\/20185584_TD0618186ENN_PDF.pdf\" target=\"_blank\" rel=\"noopener\">Acceder en ingl\u00e9s<\/a><\/p>\n<div><a href=\"http:\/\/copolad.eu\/es\/newsletter\/copolad-atlas-final?view_lang=es\" target=\"_blank\" rel=\"noopener\">Carta final COPOLAD II<br \/>\n<\/a><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/section>\n","protected":false},"excerpt":{"rendered":"<p>EMCDDA. European Monitoring Centre for Drugs and Drug Addiction What is the evidence base for the medical use of cannabis and cannabinoids? What is the difference between cannabis preparations and medicinal products and why is this important? How is this issue regulated in the EU? These and other questions are explored in this report which [&hellip;]<\/p>\n","protected":false},"author":9,"featured_media":1160,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"acf":[],"_links":{"self":[{"href":"https:\/\/copolad.fiiapp.quentalstaging.com\/es\/wp-json\/wp\/v2\/posts\/1159"}],"collection":[{"href":"https:\/\/copolad.fiiapp.quentalstaging.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/copolad.fiiapp.quentalstaging.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/copolad.fiiapp.quentalstaging.com\/es\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/copolad.fiiapp.quentalstaging.com\/es\/wp-json\/wp\/v2\/comments?post=1159"}],"version-history":[{"count":0,"href":"https:\/\/copolad.fiiapp.quentalstaging.com\/es\/wp-json\/wp\/v2\/posts\/1159\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/copolad.fiiapp.quentalstaging.com\/es\/wp-json\/wp\/v2\/media\/1160"}],"wp:attachment":[{"href":"https:\/\/copolad.fiiapp.quentalstaging.com\/es\/wp-json\/wp\/v2\/media?parent=1159"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/copolad.fiiapp.quentalstaging.com\/es\/wp-json\/wp\/v2\/categories?post=1159"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/copolad.fiiapp.quentalstaging.com\/es\/wp-json\/wp\/v2\/tags?post=1159"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}